Earnings call briefThird-quarter 2026
Bristol-Myers Squibb says it now expects legacy portfolio revenue down 3% to 5%
Chief Financial Officer David V. Elkins said on the call that the company anticipates a $1.5 billion to $2 billion Eliquis step-down in 2027.
GetSignal Bristol-Myers Squibb BMY
Chief Financial Officer David V. Elkins said on the third-quarter call that the revised 2026 revenue guidance incorporates a total legacy portfolio revenue decrease, which the company now expects to be between 3% and 5%. Bristol-Myers Squibb said it anticipates a $1.5 billion to $2 billion step-down in Eliquis revenue in 2027. Chief Executive Officer Christopher S. Boerner said the company has shared plans for a new campus in Houston, an approximately $2.3 billion investment.
Quotes from the call
“Incorporated into these revisions is a total legacy portfolio revenue decrease now expected to be between 3% to 5%...”
Key facts from the call
- Expected 2026 legacy portfolio revenue change
- Decrease of 3% to 5%
- Expected 2027 Eliquis revenue step-down
- $1.5 billion to $2 billion
- Expected strategic productivity initiative efficiencies
- $2 billion by the end of 2027
Source: Bristol-Myers Squibb's third-quarter 2026 earnings call, October 29, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Bristol-Myers Squibb now expects milvexian AFib readout in first quarter 2027
BMY Bristol-Myers Squibb Q2 2026 call
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
